acharya - Biotech, Healthcare

Biotech, Genomics, Healthcare, Pharma blog

Archives


This page is powered by Blogger. Isn't yours?
Wednesday, February 19, 2003
 
[8] News and Articles

(1) Healthcare & Pharma - Financial News, Stock Investment Research

(i) Sector Analysis - Pharmaceutical Companies, Pharma Services (ii) Sector Analysis - Biotech Companies
  • Mar 10, 2005 - Biotech: The Death Of A Dream. William Haseltine, founder of Human Genome Sciences and one of the most visible spokesmen for the promise of biotechnology, used to talk about a new era in medicine in which tailor-made gene-based products would replace drugs and "regenerative medicine" based on biotech research would result in a dramatically increased human lifespan. Haseltine, who left the company he founded last year, stated in a recent interview with Fortune magazine: "I see great inefficiencies in pharma and biotech firms. We have all these opportunities but insufficient structures to pursue them." - By Jonathan Bernstein, ETFzone Trading Specialist
  • Jan 27 2005 - Billion-Dollar Markets. Nanotech companies gets attention. That's what happened when the FDA approved American Pharmaceutical Partners' APPX new nano-based drug Abraxane. Skyepharma, Flamel Technologies, Novavax Following in their tiny footsteps. - By Carl Wherrett & John Yelovich , The Motley Fool
  • Dec 16, 2004 - Report Card 2004: Biotech Hits and Misses. Looking over all the biotech stock stories I covered in 2004, I'm pleased to report that I was right more than wrong. My "win" column does veer in the bearish direction, which is not ideal (I'd prefer more of a balance), but then there were some spectacular biotech blowups in 2004 of which I had the good fortune of being on the right side. Here, then, is my self-graded report card for 2004. - By Adam Feuerstein , The Street.com
  • Dec 08, 2004 - The Overachievers of 2004 - Biogen Idec Hits A Nerve. - By Matthew Herper, Forbes
  • Dec 06, 2004 - Celgene Can't Shake Revlimid Critics. Critics believe the company is glossing over Revlimid's safety problem and hiding the fact that more of the deaths in the study are being caused by the toxic effects of the drug - By Adam Feuerstein, TheStreet.com
  • Nov 16 2004- Finding Biotech's 50-Baggers. Finding the next Rulebreaker from more than 250 publicly traded small-cap biotech companies. - By Charly Travers , The Motley Fool
  • Nov 12, 2004 - Biotech Investors: Mark Your Calendars, Redux. Successful biotech investors keep a close eye on the calendar. Regulatory decisions and clinical trial results move this sector, so it's important to stay on top of these events whenever possible. Here's a list of noteworthy events for the rest of the year and the beginning of 2005 - By Adam Feuerstein , TheStreet.com
  • Nov 2 2004 - Biotech's 5-Baggers: Part 3. Today's approach shares last week's highly speculative approach, but with a more specific focus. Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. Such as Keryx Biopharmaceuticals (KERX), Onyx Pharmaceuticals (ONXX) - By Charly Travers, The Motley Fool
  • Sep 29 2004 - UBS Biotech Confab: To Atherogenics and Beyond. Also ---> SuperGen's moribund stock price doesn't suggest investors have much confidence in Dacogen, and it's recent partnership with MGI Pharma; Awakening Neurocrine, presentation on Indiplon, the company's experimental insomnia drug; Sepracor's drug Estorra; Unfolding Drama - for Atherogenics and its heart disease drug AGI-1067. By Adam Feuerstein , TheStreet.com
  • Oct 26 2004 - Biotech's 5-Baggers: Part 2. Today's article is about companies that have already captured the market's attention. These companies have delivered exciting, but preliminary, results that have the market thinking that these companies are onto something big, sending these stocks soaring. Such as Axonyx (AXYX), Genaera (GENR), - By Charly Travers, The Motley Fool
  • Oct 18 2004 - Biotech's 5-Baggers: Part 1. The first group of companies we'll look at have all bounced back from very serious problems to reward contrarian investors who saw a gem where the rest of the market saw trash. Such as Elan (ELN), ImClone (IMCL), Sepracor (SEPR) - By Charly Travers, The Motley Fool
  • Sep 01 2004 - The Time Is Right for These Seven Biotechs. Group 1: Three Profitable Big-Cap Biotech Leaders - Amgen, Chiron, Genentech, Group 2: Four Unprofitable Companies With Potentially Huge Pipelines - Cell Genesys, Incyte, NPS Pharmaceuticals , Onyx Pharmaceuticals. - By Jim Jubak, MSN Money Markets Editor, TheStreet.com
  • Aug 10 2004 - Biotech Cost Control Highlighting the investing cycles in the Biotech sector - By Brian Gorman , Motley Fool
  • April 2004 - Bargain Hunting in Big Biotech. MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors. - By Charly Travers, The Motley Fool
  • Sep 9, 2003 - Speculating in Biotech (Story of Praecis Pharmaceuticals). Motley Fool, By Tom Jacobs
  • Sep 2003 - 'Murky' data leave doubt over Genta, Aventis drug. Reuters, By Ransdell Pierson and Ben Hirschler
  • Sep 2003 - Aventis, Regeneron Sign $510 Mln Deal - A Rich French Uncle, SmartMoney.com, By Lawrence Carrel
  • Sep 2003 - Elan: One Ailing Celtic Tiger. Accounting woes and disappointing drugs have the once fierce Irish biotech bogged down. Businessweek
  • Aug 2003 - Nektar Therapeutics Announces Second Quarter 2003 Results. Press Release. (Most significant drug = Exubera. NKTR working with Pfizer and Aventis)
  • Aug 2003 - Celltech Group plc Announces Interim Report for the Six Months Ended 30 June 2003 (including Drugs Pipeline), Press Release.
  • July 2003 - Flamel Technologies: The Good News Is Out. Josh Wolfe, Forbes/Wolfe Nanotech Report
  • Mar 2003 - Small Pharma Offers Investing Alternative - Forbes article
  • Mar 2002 - Biotech's New Colossus - Move over, Big Pharma. Amgen boasts better growth. - FORTUNE, By David Stipp
(iii) Sector Analysis - Biomedical Devices & Medical Equipment
  • Feb 04 2005 - Cyberonics' Depression Zapper. Shares of this neurology device company have oscillated violently between the low teens and upper 30s, alternately built up and beaten down, as the company has sought FDA approval to use its Vagus Nerve Stimulation (VNS) Therapy System on severely depressed patients who don't respond to other treatment. - By Stephen D. Simpson, Motley Fool
  • Feb 01 2005 - Boston Scientific plans to stay on top in stents. Medical device maker Boston Scientific Corp. BSX on Tuesday forecast profit growth in 2005 in excess of 23 percent, on the heels of a blockbuster year marked by the introduction of its Taxus drug-coated stent. - Reuters via Yahoo News
(iv) Sector Analysis - HMO sector, Healthcare Insurance and Benefits Groups, Pharmacy Benefits PBMs
  • Apr 12, 2005 - Healthy Hopes for HMO Numbers. As first-quarter results come out this week, Goldman Sachs analyst Matthew Borsch suggests that investors focus on the strongest names in the pack. He points to WellPoint WLP as his favorite pick. Meanwhile, he singles out Coventry CVH as the most challenged player in the group. - By Melissa Davis, TheStreet.com
  • Mar 29, 2005 - Pressure Builds on Medco, Peers. Wall Street analysts pay little notice to potential hazards of Medicaid investigations. By now, they have seen PBMs face multiple legal challenges and emerge virtually unscathed. Thus, they tend to focus more on the sector's opportunities -- such as the new Medicare drug benefit -- than on its potential risks. - By Melissa Davis, TheStreet.com
  • Mar 18, 2005 - Managing the Unmanageable. American Healthways offers specialized programs to help health-care plans and self-insured companies more effectively treat and manage patients with certain conditions. - By Stephen D. Simpson, CFA , The Motley Fool
  • Mar 03, 2005 - Battles Mounting at Medco, Caremark. By now, all three major PBMs have managed to beat fourth-quarter earnings expectations and raise hopes for the current year. Still, Medco, Express Scripts and Caremark carry with them the risk of serious side effects. - By Melissa Davis, TheStreet.com
  • Feb 22, 2005 - Coventry Gets a Bad Rap. Although it has a very good track record of growth and achieving expectations, management nevertheless believes that growth over the past few quarters has been "unacceptable" and that the company can do even better. - By Stephen D. Simpson , The Motley Fool
  • Feb 17, 2005 - Caremark Hits the Mark Again. Business was strong again for Caremark in the fourth quarter. Sales grew 9% on a pro-forma basis (treating the earnings as though the acquired AdvancePCS business had been included in '03 results), and net income grew 51%. - By Stephen D. Simpson, Motley Fool
  • Feb 03, 2005 - HMO Stocks Are on Shaky Ground. The managed care sector -- long a strong performer -- is showing signs of weakness. PacifiCare's upbeat report came just days after Douglas Holtz-Eakin, head of the Congressional Budget Office, warned of the need to control the escalating costs of Medicare and Medicaid. - By Melissa Davis, TheStreet.com
  • Feb 01, 2005 - Loyalty Strained at Caremark. Caremark's relationships with many of its biggest customers are looking increasingly unhealthy. States investigate the other large PBMs, Medco and ExpressScripts too. - By Melissa Davis, TheStreet.com
  • Jan 11 2005 - HMOs Looking Peaked. On Monday, the U.S. Supreme Court upheld a lower-court ruling that could lead to huge settlement bills for some giant health management organizations. The ruling opens the door for a September trial against six HMOs accused of conspiring to violate federal law by failing to properly pay physicians. CVH, HNT, HUM, UNH, PHS and WLP involved.
    Further, analysts look at hospital stock THC, and two dialysis providers, DVA and RCI
  • Dec 29, 2004 - 2005 Trend: HMOs Face Pricing Headwinds. For years, double-digit premium increases have kept profits -- and stock prices -- soaring in the health insurance sector. Thus, companies like UnitedHealth UNH and WellPoint WLP have consistently ranked among the healthiest performers in the market. But recent trends indicate that industry doubters, who have long warned of an inevitable downturn, may soon be proven right. - By Melissa Davis, TheStreet.com
  • Dec 13, 2004 - PacifiCare buys American Medical Security Group. PHS said early Monday that it has completed its $505 million purchase of AMSG. - By Laura Gilcrest, CBS MarketWatch
  • Nov 26, 2004 - HMOs Hurry to Cash In on Savings Shift. Managed Care companies are rolling out "consumer-driven" health savings accounts that, some believe, will help reshape health care coverage in this country. - By Melissa Davis, TheStreet.com
  • Nov 23, 2004 - Express Scripts Fans Wonder What's Cooking. Wall Street is hungry for some Express Scripts news. The pharmacy benefit manager plans to release its delayed 2005 outlook Wednesday, ahead of the long Thanksgiving weekend. Some observers are now worrying about just what the company will serve up. - By Melissa Davis, TheStreet.com
  • Oct 25 2004 - Medco, Peers Face New Test From Clients. Keeping secrets -- and the profits they can generate -- is starting to get tougher for pharmacy benefit managers, or PBMs. -By Melissa Davis, TheStreet.com
  • Oct 19, 2004 - Spitzer Fears Flog Health Stocks. Managed care stocks -- long among the healthiest performers in the group -- took a pounding Tuesday over fears about a sweeping probe of the insurance industry announced last week by New York Attorney General Eliot Spitzer. News of a fresh subpoena fielded by UnumProvident, the nation's largest provider of disability insurance, triggered an industrywide selloff. -By Melissa Davis, TheStreet.com
  • Sep 30, 2004 - Wall Street Is Standing by Medco, Caremark. Some people believe that pharmacy benefit managers -- and the Wall Street analysts who follow them -- are in a state of denial about the industry's future. -By Melissa Davis, TheStreet.com
  • Sep 15, 2004 - PacifiCare Pushes Beyond Medicare. The California-based health insurer, which caters primarily to the Medicare population, announced on Wednesday that it is acquiring a growing provider of health savings accounts. PacifiCare is offering a 41% premium to shareholders of American Medical Security Group. -By Melissa Davis, TheStreet.com
  • Aug 16 2004 - Medco and Its Peers Brace for a Flank Attack. The embattled pharmacy benefit management industry could soon face competition from its own customers. Dozens of companies -- including big names like IBM -- have joined forces in an effort to directly negotiate with drug manufacturers for discounts on their own. - By Melissa Davis, TheStreet.com
  • Aug 04, 2004 - Spitzer Takes Aim at Express Scripts. The pharmacy benefits manager faces up to $100 million in damages for allegedly defrauding customers in New York. There, Attorney General Eliot Spitzer on Wednesday filed a lawsuit accusing the company of engaging in a "complicated pricing scheme" in an effort to enrich itself at the expense of the customers it is supposed to be helping. - By Melissa Davis, TheStreet.com
  • Jul 15, 2004 - UnitedHealth Powers Ahead. The company posted second-quarter profits of 93 cents a share -- beating the consensus estimate by a penny -- despite soft enrollment numbers in certain business segments. It also raised its earnings forecast for the full year to between $3.79 and $3.82 a share, excluding any gains from its upcoming purchase of Oxford Health. - By Melissa Davis, TheStreet.com
(v) Sector Analysis - Medical Supplies, Distributors, Healthcare IT and Operations
  • Feb 8 2005 - Eclipsys shares fall, '05 outlook below some views. Eclipsys, a provider of health care information systems, fell 11 percent after the company's 2005 outlook fell below some analysts' expectations, an analyst at Piper Jaffray said on Tuesday. - Reuters via Yahoo News
  • Feb 4 2005 - Cardinal Back in the Red. Once again, the health care giant has delivered an earnings miss and scaled back expectations that skeptics had doubted the company could meet. Yet the company remains upbeat, still promising a strong recovery that has proven elusive so far. - By Melissa Davis, Senior Writer, TheStreet.com
  • Feb 3 2005 - IDX Fourth Quarter 2004 Earnings Results Conference Call, February 10, 2005. IDX Systems Corporation is a leading provider of healthcare information systems. - IDX Systems Corporation Press Release
  • Jan 21 2005 - Cardinal Back in the Nest. In the end, maybe they both blinked. Just days after announcing that they couldn't come to an agreement and sending out alerts to health-care providers and pharmacies nationwide, drug distributor Cardinal Health and Japanese pharmaceutical company Eisai reported that they found common ground after all. - By Rich Duprey , Motley Fool
  • Jan 18 2005 - Cardinal Doesn't Get Ruffled. Cardinal's difficulty with Japanese pharmaceutical firm Eisai is just the latest development in the drug wholesaler's effort to get pharmaceutical manufacturers to accede to a fee-for-service system for drug distribution - By Brian Gorman , Motley Fool
  • Nov 16 2005 - Cerner to Acquire VitalWorks' Medical Division, a Leader in Physician Office Technologies. Transaction Expands Healthcare IT Company's Strength in the Physician Practice Market. - Cerner Corporation Press Release
(vi) Sector Analysis - Hospitals, Rehab, Long-term care, Nursing Homes


(2) Scientific and Biotech Product News and Articles

(i) Pharmaceutical News

  • Feb 18 2005 - For FDA Panel, Big Question Is Why?. The future of the arthritis treatments Celebrex, Bextra and Vioxx may rest on a question of basic science: Why would all three drugs increase the risk of heart attack and stroke, at least at high doses?
    Two competing theories seem to be shaping the thinking of the U.S. Food and Drug Administration advisory panel that is likely to decide the fate of these medicines - Celebrex, Bextra and Vioxx. - By Matthew Herper, Forbes
  • Sep 2003 - Merck dips toe into new era of anti-RNA drugs. Reuters, Sep 2003, By Ransdell Pierson. (Merck works with Cambridge, Massachusetts-based Alnylam Holding Co, which is founded by Phillip Sharp, a professor at the Massachusetts Institute of Technology who won a 1993 Nobel Prize for discovering RNA-interference)
  • May 2003 - Big Pharma's Research Drought Ends After the worst year ever for new drug approvals, drug firms relearn how to discover medicines. - Matthew Herper, Forbes
  • robin henig
(ii) Biotech Industry News

(iii) Cancer Drugs news

  • May 16, 2005 - Celgene's Revlimid Effective vs. Blood Cancer. Revlimid can eliminate a genetic abnormality causing the most common blood cancer, researchers announced at this year's annual meeting of the American Society of Clinical Oncology. - By Althea Chang, TheStreet.com
  • May 16, 2005 - Genentech, Pfizer Shine at Cancer Conference. Genentech's Avastin, Pfizer's experimental drug Sutent, Bayer and Onyx Pharmaceuticals drug for renal cell carcinoma, Novartis and Schering treatment for colorectal cancer, GlaxoSmithKline's Bexxar, MedImmune's treatment for metastatic melanoma, Cell Therapeutics's Xyotax, Telik's Telcyta , Amgen and Johnson & Johnson results of their products for fighting chemotherapy-induced anemia, Celgene reporting on thalidomide used against multiple myeloma, OSI Pharmaceuticals' Tarceva for advanced pancreatic cancer.
    This article compiles the major stories that emerged over the weekend at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla. Staff Reporter Althea Chang has been providing this year's coverage for TheStreet.com
  • Mar 7, 2005 - Celgene lifts biotech stocks at close. A positive trial for a cancer drug lifted the shares of Celgene Monday, as both biotechnology and pharmaceutical stocks ticked up at the close.
    The converse, however, was true for Cell Therapeutics, which said its Xyotax treatment, used in conjunction with other drugs, did not achieve its primary goals in treatment of lung cancer.
    A third biotech firm, Geron Corp., put out a release saying that its treatment for HIV and AIDS was showing signs of effectiveness, according to recent data. - By Russ Britt, MarketWatch
  • Jan 11, 2005 - The Future of Cancer Vaccines. Biotech companies developing cancer vaccines have been in investors' doghouses for a long time - Dendreon DNDN, Cell Genesys CEGE, Biomira BIOM. These companies tend to have valuations much lower than companies developing small-molecule or monoclonal antibody drugs for cancer. Much of the skepticism toward these companies is warranted given the lack of a successful cancer vaccine. - By Charly Travers, The Motley Fool
  • Jan 3, 2005 - SuperGen - Stumbling Over a Regulatory Hurdle. Shares of SuperGen (SUPG) fell 13.5% to $6.10 Monday after the drug maker withdrew its U.S. application for a pancreatic cancer treatment. - By Lawrence Carrel , SmartMoney.com
  • Dec 24, 2004 - FDA clears Genzyme leukemia drug. GENZ and Bioenvision BIVN shares rally on Clolar's approval. Drug treatment is for the most common type of childhood leukemia - By Ciara Linnane, CBS.MarketWatch.com
  • Dec 9, 2004 - Pretty in Pink Ribbon. Shares of Introgen Therapeutics (INGN) climbed 15% to $8.82 Thursday after the drug developer announced that its experimental cancer treatment, Advexin, proved effective in shrinking tumors when used in conjunction with chemotherapy. - SmartMoney
  • Dec 3 2004 - One Hot Biotech Stock. Biomira announced favorable Phase II trial results for its non-small-cell lung cancer (NSCLC) treatment. - By W.D. Crotty, Motley Fool
  • OSI Pharmaceuticals and Genentech - Tarceva
  • Aug 16 2004 - Avastin's Stumble, Genentech's Tumble. A complications warning concerning the blockbuster drug was a small setback, but it knocked the wind out of the biotech's stock. - By Arlene Weintraub, Business Week
  • Apr 2004 - Genentech Hits Another Home Run - Matthew Herper, Forbes
  • Mar 2004 - Genzyme's Oncology Acquisitions - By David Nierengarten, The Motley Fool
  • Aug 2003 - On the Twisting Trail of Cancer Vaccines. While success has eluded huge drug companies and small biotechs so far, scientists now have a better idea of what might work - Businessweek, By Amy Tsao and John Carey
  • Aug 2003 - The End of Cancer (As we Know it). Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. - By Jennifer Kahn, Wired Mag
(iv) Diabetes, Cholesterol, Heart disease, Hypertension, Blood Pressure Drugs

(v) Brain, neurological Drugs news - also Multiple Sclerosis, Arthritis, Sleep, Alzhemiers, Memory, Psychiatric, Depression

  • Feb 28, 2005 - Biogen Idec and Elan pull MS drug. Biogen Idec and Elan Corp. shares plummeted in heavy volume Monday after the companies said they have voluntarily suspended sales and trials of their Tysabri treatment for multiple sclerosis because of safety concerns. - By Michael Baron, MarketWatch
  • Nov 30 2004 - Biogen Idec Reaffirms Outlook. CFO says company has the third highest profit margins in the biotech industry. On Nov 23 2004, FDA approved Tysabri (Antegren), the much-awaited MS drug developed and marketed with Elan. "Tysabri is the tip of the iceberg".
    Tysabri is one of several drugs being tested for other uses. For example, the company expects phase II clinical trial results in mid-2005 for Tysabri as a treatment for rheumatoid arthritis. - By Robert Steyer, TheStreet.com
  • Nov 24 2004 - Biogen, Elan shares move on FDA OK of Antegren. - By Carolyn Pritchard & Ciara Linnane, CBS Marketwatch
  • Sep 30 2004 - Alzheimer's Payday Eludes Drugmakers Heroic failures -- that's how medical data firm IMS Health described the quest to find a cure for Alzheimer's disease in 2000. But Neurochem (NRMX) and Axonyx (AXYX) are still innovating - By Robert Steyer, TheStreet.com
(vi) AIDS, SARS, infectious diseases news

(vii) Biomedical Devices news

  • Dec 1 2004 - One-Day Wonder, GeoPharma's (GORX) shareholders found themselves on quite the roller coaster ride on Dec 1 2004, after the maker of dietary supplements announced that its Belcher Pharmaceuticals subsidiary had received Food and Drug Administration approval for Mucotrol, a prescription product to treat painful mouth sores.
    Perhaps adding to the skepticism over the stock is the fact that GeoPharma's chairman is Jugal Taneja, who has already headed at least two other publicly traded health-care companies that failed. NuMed Home Health Care in Clearwater, Fla., went bankrupt in 2000, and National Diagnostics of Brandon, Fla., declared bankruptcy in 2001. - By Lawrence Carrel, SmartMoney.com
  • Aug 14, 2004 - Checking In With Biotech - By Adam Feuerstein, TheStreet.com
    • Cyberonics CYBX shares continued to fall Monday after last week's Food and Drug Administration decision to reject the company's nerve-stimulation device to treat severe depression.
    • Changing of the Guard at BioMarin
    • Flunking BioVail even though the Canadian drugmaker BVF reported second-quarter earnings Aug. 4 that beat Wall Street expectations
    • InterMune ITMN Goes Deeper Into Hiding
  • July 2003 - Nothing Limp about Health-Care Equipment. Even after the sector's big strides in 2003, analysts see stocks chalking up gains. Businessweek
(viii) Endocrinology, Reproductive, Sexual Function, Hormonal drug news

  • Nov 29, 2004 - Quest for Desire. After decades of neglect, drugmakers are closer than ever to finding a prescription for a malady in millions of women: lack of sexual desire. Companies covered include Procter and Gamble P&G, Pfizer/Viagra, Eli Lilly & ICOS/Cialis, Nastech, NexMed, Solvay and Vivus - By Allisson Fass, Forbes



(3) Healthcare Industry - hospitals, physicians, insurance providers, drug manufacturers and distributors

(i) HMOs and Health Insurance industry News

(ii) Drug manufacturing, marketing and distrbution News

  • Sep 30 2004 - Wall Street Is Standing by Medco, Caremark. Some people believe that pharmacy benefit managers , PBMs -- and the Wall Street analysts who follow them -- are in a state of denial about the industry's future. PBMs have increasingly become targets of government investigators who suspect them of unfairly profiting at their customers' expense - By Melissa Davis, Senior Writer, TheStreet.com
  • Meet Cardinal Health's Bob Walter, builder of a $51 billion stealth empire. - By Adam Lashinsky, FORTUNE, Sunday, March 30, 2003



(4) Biology News

(i) Genomics, Proteomics

  • Apr 2004 - Venter Makes Waves -- Again. This Spring, J. Craig Venter is sailing around the French Polynesian Islands scooping up bucketfuls (figuratively) of seawater in an ambitious voyage to sample microbial genomes found in the world's oceans. - By John Russell , Bio-IT World
  • Apr 2003, 50th anniversary of the double helix - Beyond the blueprint. As investigators celebrate the golden anniversary of the double helix, how will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? - BY MALORYE BRANCA, BioIT World
  • Apr 2003, 50th anniversary of the double helix - Genes, Girls, and Honest Jim. Honest Jim Watson remains as charming, humorous, obstinate, and outrageous as ever, in this BioITWorld interview.
  • Apr 2003, 50th anniversary of the double helix - An interview with J. Craig Venter: Beyond the Human Genome. - By Kevin Davies , Bio-IT World
  • May 2002 - Craig Venter forms nonprofits. - By George A. Chidi, Jr. , IDG News Service, Boston Bureau




posted by S at 8:47 AM

HOME